It included 10,061 patients with a history of myocardial infarction and elevated ultrasensitive C-reactive protein (hsCRP ≥ 2 mg/L) who received canakinumab (50 mg, 150 mg or 300 mg) or placebo, administered subcutaneously every 3 months, with a median follow-up of 3.7 years [190]. Here, CRP is linked to myocardial infarction.